The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.
 
David Lawrence Bajor
Consulting or Advisory Role - Seagen
Research Funding - Abbvie (Inst); Ascendis Pharma (Inst); Immunicum (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Tesaro/GSK (Inst); Top Alliance Bioscience (Inst)
 
AMR MOHAMED
No Relationships to Disclose
 
J. Eva Selfridge
Research Funding - Tizona Therapeutics, Inc. (Inst); Vigeo Therapeutics (Inst)
 
Erin E. Anderson
No Relationships to Disclose
 
Jeffrey Hardacre
No Relationships to Disclose
 
John Brian Ammori
No Relationships to Disclose
 
Richard T. Lee
Research Funding - Merck (Inst); TRACON Pharma (Inst)
Other Relationship - Grow Ohio Pharmaceuticals
 
Joel N. Saltzman
Stock and Other Ownership Interests - novartis; Roche
Consulting or Advisory Role - IBM
 
Jordan Michael Winter
No Relationships to Disclose